RxDoctor Payments Data

Kyle Gronberg

Nurse Practitioner · Springfield, MONPI 1427773852

Payments from drug & device makers

$3,020in general payments, 2019–2025

Across 94 payments — averaging $32.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • AbbVie$375
  • Novartis$110
  • EMD Serono, Inc.$96
  • Acorda Therapeutics, Inc$83
  • Abbott$74
  • plus $871 from 25 others

What the payments were for

  • Travel & lodging$1,04835%
  • Food & beverage$1,97265%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,020 in reported general payments places this provider in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

See all nurse practitioner providers in Missouri

Medicare billing

Part B allowed, 2024
$4,839
Medicare patients
78
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant14$20,110
LamictalLamotrigine23$18,279
Aimovig AutoinjectorErenumab-Aooe25$17,881
QuliptaAtogepant12$16,616
Entacapone24$10,798
Levetiracetam212$4,948
DilantinPhenytoin Sodium Extended18$4,131
Lamotrigine168$2,548
Primidone78$2,312
Topiramate137$2,227
Oxcarbazepine40$2,177
Gabapentin99$1,768
Carbidopa-LevodopaCarbidopa/Levodopa42$1,699
Memantine Hcl66$1,271
Divalproex Sodium13$1,002

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$375$36,72526 claims
PfizerDilantin$34$4,13118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,898 nurse practitioner providers in Missouri.

Other nurse practitioner in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →